{"id":"W3031031270","doi":"10.3747/co.27.5495","title":"Treatment of Non-Small-Cell Lung Cancer after Progression on Nivolumab or Pembrolizumab","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; University of Victoria","funders":"","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Erlotinib; Lung cancer; Hazard ratio; Docetaxel; Oncology; Confidence interval; Cancer; Immunotherapy; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003232814,0.0001155154,0.0003105729,0.0001874464,0.0003815652,0.0003525784,0.0002381638,0.000204326,0.0009844707],"category_scores_gemma":[0.0007074953,0.00005877829,0.000367125,0.0002939218,0.0001595767,0.0001486501,0.0002195609,0.0004607829,0.0001232147],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000981199,"about_ca_system_score_gemma":0.001215852,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005912851,"about_ca_topic_score_gemma":0.02107013,"domain_scores_codex":[0.9997875,0.0000367127,0.00001815231,0.00003499534,0.0000611441,0.00006149169],"domain_scores_gemma":[0.9993969,0.0001221325,0.0002224523,0.000019605,0.00005927512,0.0001796015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002016067,0.0002563049,0.9690387,0.0001270541,0.0001372465,0.0009416786,0.00007380695,0.0004461822,0.002251568,0.00005140678,0.0008693988,0.02379055],"study_design_scores_gemma":[0.00008659087,0.001156547,0.994919,0.00002901059,0.00006384786,0.001395975,0.00007837775,0.0005556845,0.0004861513,0.00006550399,0.001159294,0.000003905575],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99805,0.0006832822,0.00005747267,0.0001013943,0.000006994317,0.00002226062,0.0002164912,0.000004885088,0.0008572048],"genre_scores_gemma":[0.999012,0.0002436436,0.00006170237,0.0000581399,0.00001371997,0.00001091534,0.0004204527,9.599672e-7,0.0001784173],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005912851,"threshold_uncertainty_score":0.01175684,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07456514527921008,"score_gpt":0.4123760241915838,"score_spread":0.3378108789123737,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}